Oxford Gene Technology (OGT), provider of genetics research and biomarker solutions for molecular medicine, launched its new CytoSure Consortium Cancer +SNP array (4x180k) at the recent Cancer Cytogenomics Microarray Consortium (CCMC) and Cytogenomics Array Group (CAGdb) combined meeting.
The new CytoSure Consortium Cancer +SNP array allows the simultaneous detection of copy number variation (CNV) and loss of heterozygosity (LOH), with a SNP resolution that enables reporting of LOH at 10 Mb. Focusing on content recommended by the CCMC, an international organization of clinical cytogeneticists, molecular cytogeneticists, and molecular pathologists, this targeted array covers more than 500 cancer genes and 130 cancer-associated genomic regions for hematological malignancies and solid tumors.
The new array is the latest addition to a range of OGT microarrays designed for detecting CNV and LOH on a single array for cancer research. This includes the recently released CytoSure Cancer +SNP array (4x180k), covering 1,500 cancer-associated genes, and the CytoSure Hematological Cancer +SNP array (8x60k) focused specifically on hematological cancers. Due to the unique design of OGT’s SNP probes, there are no changes to the standard aCGH protocol, no restriction digest is required, and any reference sample can be used. This enables the use of matched samples, which is a particular advantage in cancer research, allowing constitutional abnormalities to be filtered out. OGT’s CytoSure Interpret Software is supplied with all CytoSure arrays, delivering reliable data analysis. Learn more about CytoSure Consortium Cancer +SNP array and other research-use-only products and services offered by OGT.
